309 related articles for article (PubMed ID: 19900212)
1. A randomized, 36-month, post-marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-prostaglandin therapy in patients with glaucoma or ocular hypertension.
Friström B; Uusitalo H
Acta Ophthalmol; 2010 Feb; 88(1):37-43. PubMed ID: 19900212
[TBL] [Abstract][Full Text] [Related]
2. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.
Olander K; Zimmerman TJ; Downes N; Schoenfelder J;
Clin Ther; 2004 Oct; 26(10):1619-29. PubMed ID: 15598478
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.
Uusitalo H; Pillunat LE; Ropo A;
Acta Ophthalmol; 2010 Feb; 88(1):12-9. PubMed ID: 20420586
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure.
Shin DH; Feldman RM; Sheu WP;
Ophthalmology; 2004 Feb; 111(2):276-82. PubMed ID: 15019375
[TBL] [Abstract][Full Text] [Related]
5. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
6. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.
Bournias TE; Lai J
Ophthalmology; 2009 Sep; 116(9):1719-24. PubMed ID: 19592108
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension.
Lesk MR; Koulis T; Sampalis F; Sampalis JS; Bastien NR
Ann Pharmacother; 2008 Apr; 42(4):498-504. PubMed ID: 18364402
[TBL] [Abstract][Full Text] [Related]
8. Switch to latanoprost monotherapy from combined treatment with beta-antagonist and other antiglaucoma agents in patients with glaucoma or ocular hypertension.
Ito K; Goto R; Matsunaga K; Sugimoto K; Uji Y
Jpn J Ophthalmol; 2004; 48(3):276-80. PubMed ID: 15175922
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
[TBL] [Abstract][Full Text] [Related]
10. Feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid Health Maintenance Organization.
Law SK; Song BJ; Fang E; Caprioli J
Ophthalmology; 2005 Dec; 112(12):2123-30. PubMed ID: 16225924
[TBL] [Abstract][Full Text] [Related]
11. A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure.
Choplin N; Bernstein P; Batoosingh AL; Whitcup SM;
Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S19-25. PubMed ID: 15016558
[TBL] [Abstract][Full Text] [Related]
12. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components.
Diestelhorst M; Larsson LI;
Ophthalmology; 2006 Jan; 113(1):70-6. PubMed ID: 16263174
[TBL] [Abstract][Full Text] [Related]
13. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
[TBL] [Abstract][Full Text] [Related]
14. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial.
Walters TR; DuBiner HB; Carpenter SP; Khan B; VanDenburgh AM;
Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S26-35. PubMed ID: 15016559
[TBL] [Abstract][Full Text] [Related]
15. Using diurnal intraocular pressure fluctuation to assess the efficacy of fixed-combination latanoprost/timolol versus latanoprost or timolol monotherapy.
Varma R; Hwang LJ; Grunden JW; Bean GW
Br J Ophthalmol; 2010 Jan; 94(1):80-4. PubMed ID: 19692375
[TBL] [Abstract][Full Text] [Related]
16. Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy.
Liu JH; Medeiros FA; Slight JR; Weinreb RN
Ophthalmology; 2009 Mar; 116(3):449-54. PubMed ID: 19157559
[TBL] [Abstract][Full Text] [Related]
17. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group.
Bucci MG
J Glaucoma; 1999 Feb; 8(1):24-30. PubMed ID: 10084271
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dorzolamide/timolol fixed combination after 2 and 6 months of treatment.
Konstas AG; Kozobolis VP; Tsironi S; Makridaki I; Efremova R; Stewart WC
Ophthalmology; 2008 Jan; 115(1):99-103. PubMed ID: 18166407
[TBL] [Abstract][Full Text] [Related]
19. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
[TBL] [Abstract][Full Text] [Related]
20. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost.
Miura K; Ito K; Okawa C; Sugimoto K; Matsunaga K; Uji Y
J Glaucoma; 2008; 17(3):233-7. PubMed ID: 18414111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
